TABLE 1.
Characteristics of included studies.
| References | Studies | Country | Trials type | Sample size | Age (Mean ± SD); | Chemotherapy | Dosage of VE | Outcomes | Diagnostic method of CIPN | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VE | Con | VE | Con | ||||||||
| Anoushirvani et al. (2018) | Pace et al. (2003) | Italy | RCT | 13 | 14 | 58.0 ± 8.2 | 57.0 ± 11.7 | Cisplatin | 300 mg/d | IPN, TNS | NA, CP, NE |
| Pace et al. (2003) | Argyriou et al. (2005) | Greece | RCT | 16 | 15 | 55.8 ± 12.6 | 57.5 ± 11.4 | Cisplatin, Paclitaxel | 600 mg/d | IPN | NA, CP, NE |
| Argyriou et al. (2005) | Argyriou et al. (2006b) | Greece | RCT | 18 | 19 | 56.8 ± 8.3 | 57.2 ± 11.5 | Paclitaxel | 600 mg/d | IPN, TNS | NA, CP, NE |
| Argyriou et al. (2006a) | Argyriou et al. (2006a) | Greece | RCT | 14 | 16 | 53.6 ± 14.8 | 59.3 ± 12.8 | Cisplatin | 600 mg/d | IPN, TNS, AE | NA, CP, NE |
| Argyriou et al. (2006b) | Pace et al. (2010) | Italy | RCT | 17 | 24 | 58.0 ± 11.0 | 58.5 ± 10.7 | Cisplatin | 400 mg/d | IPN, TNS | NA, CP, NE |
| Pace et al. (2010) | Kottschade et al. (2011) | USA | RCT | 96 | 93 | / | / | Taxanes, Cisplatin, carboplatin, Oxaliplatin, or combination | 600 mg/d | IPN | NA, CP |
| Kottschade et al. (2011) | Afonseca et al. (2013) | Brazil | RCT | 18 | 16 | 56.0 ± 12.0 | 57.0 ± 7.9 | Oxaliplatin | 400 mg/d | IPN, AE | NA, CP |
| Afonseca et al. (2013) | Salehi et al. (2015) | Iran | RCT | 32 | 33 | 56.0 ± 14.3 | 58.9 ± 13.6 | Oxaliplatin | 400 mg/d | IPN, TNS | NA, CP |
| Salehi and Roayaei (2015) | Anoushirvani et al. (2018) | Iran | RCT | 21 | 21 | 50.9 ± 10.4 | 52.2 ± 10.1 | Paclitaxel | 600 mg/d | IPN | NA, CP, NE |
RCT, randomized controlled trial; VE, vitamin E; Con, control; IPN, incidence of peripheral neuropathy; TNS, total neuropathy scores; AE, adverse events; NA, neurologic assessment; CP, clinical presentation of CIPN; NE, Neurophysiological examination.